{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,10]],"date-time":"2026-10-10T16:42:35Z","timestamp":1791650555870,"version":"4.3.4"},"reference-count":85,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100003803","name":"HKU","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003803","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100005847","name":"Health and Medical Research Fund","doi-asserted-by":"publisher","award":["11220196"],"award-info":[{"award-number":["11220196"]}],"id":[{"id":"10.13039\/501100005847","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","surveyophthalmol.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Survey of Ophthalmology"],"published-print":{"date-parts":[[2026,11]]},"DOI":"10.1016\/j.survophthal.2026.04.002","type":"journal-article","created":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T22:18:08Z","timestamp":1777673888000},"page":"1732-1745","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"title":["Efficacy, tolerability, and threshold effect of atropine eye drops for myopia control: A systematic review and dose-response meta-analysis"],"prefix":"10.1016","volume":"71","author":[{"given":"Xiu Juan","family":"Zhang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mingming","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marco","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Edison Chak Fung","family":"Ho","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ryan Tak Chun","family":"Wong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ebenezer","family":"Zaabaar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Weijia","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haiyan","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philip Yawen","family":"Guo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jing","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexander Ka-Ngai","family":"Lam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ching-Yu","family":"Cheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jason C.","family":"Yam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kendrick Co","family":"Shih","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"suffix":"MD, MB ChB","given":"Christopher Kai Shun","family":"Leung","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"4","key":"10.1016\/j.survophthal.2026.04.002_bib1","doi-asserted-by":"crossref","first-page":"111","DOI":"10.3329\/bsmmuj.v13i4.50499","article-title":"Topical atropine in retarding myopia progression and axial length growth in children with myopia","volume":"13","author":"Alam","year":"2020","journal-title":"Banga Sheikh Mujib Med Univ J"},{"key":"10.1016\/j.survophthal.2026.04.002_bib2","doi-asserted-by":"crossref","DOI":"10.1016\/j.preteyeres.2020.100923","article-title":"Efficacy in myopia control","volume":"83","author":"Brennan","year":"2021","journal-title":"Prog Retin eye Res"},{"issue":"3","key":"10.1016\/j.survophthal.2026.04.002_bib3","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1111\/opo.12686","article-title":"Myopia control 2020: where|ding?","volume":"40","author":"Bullimore","year":"2020","journal-title":"Ophthalmic Physiol Opt"},{"issue":"7","key":"10.1016\/j.survophthal.2026.04.002_bib4","doi-asserted-by":"crossref","first-page":"771","DOI":"10.1016\/j.ophtha.2023.02.020","article-title":"Efficacy in myopia control: the low-concentration atropine for myopia progression (LAMP) study","volume":"130","author":"Bullimore","year":"2023","journal-title":"Ophthalmology"},{"issue":"1","key":"10.1016\/j.survophthal.2026.04.002_bib5","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1111\/opo.13403","article-title":"Efficacy in myopia control\u2014The impact of rebound","volume":"45","author":"Bullimore","year":"2025","journal-title":"Ophthalmic Physiol Opt"},{"issue":"1","key":"10.1016\/j.survophthal.2026.04.002_bib6","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-022-15686-6","article-title":"Efficacy of 0.01% atropine for myopia control in a randomized, placebo-controlled trial depends on baseline electroretinal response","volume":"12","author":"Chan","year":"2022","journal-title":"Sci Rep"},{"issue":"2","key":"10.1016\/j.survophthal.2026.04.002_bib7","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1016\/j.ophtha.2011.07.031","article-title":"Atropine for the treatment of childhood myopia: safety and efficacy of 0.5%, 0.1%, and 0.01% doses (Atropine for the Treatment of Myopia 2)","volume":"119","author":"Chia","year":"2012","journal-title":"Ophthalmology"},{"issue":"2","key":"10.1016\/j.survophthal.2026.04.002_bib8","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1016\/j.ophtha.2015.07.004","article-title":"Five-year clinical trial on atropine for the treatment of myopia 2: myopia control with atropine 0.01% Eyedrops","volume":"123","author":"Chia","year":"2016","journal-title":"Ophthalmology"},{"issue":"4","key":"10.1016\/j.survophthal.2026.04.002_bib9","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1097\/APO.0000000000000609","article-title":"Atropine ophthalmic solution to reduce myopia progression in pediatric subjects: the randomized, double-blind multicenter phase II APPLE study","volume":"12","author":"Chia","year":"2023","journal-title":"Asia-Pac J Ophthalmol"},{"issue":"9","key":"10.1016\/j.survophthal.2026.04.002_bib10","first-page":"641","article-title":"Ophthalmologists association,chinese doctor association. expert consensus on application of low-concentration atropine eye drops in the prevention and control of myopia in children and adolescents (2024)","volume":"26","author":"Chinese Optometric Association COSOaOC","year":"2024","journal-title":"Chin J Optom Ophthalmol Vis Sci"},{"issue":"1","key":"10.1016\/j.survophthal.2026.04.002_bib11","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2021.43781","article-title":"Evaluation of an optical defocus treatment for myopia progression among schoolchildren during the COVID-19 pandemic","volume":"5","author":"Choi","year":"2022","journal-title":"JAMA Netw Open"},{"issue":"12","key":"10.1016\/j.survophthal.2026.04.002_bib12","doi-asserted-by":"crossref","first-page":"2285","DOI":"10.1016\/j.ophtha.2006.05.062","article-title":"Atropine for the treatment of childhood myopia","volume":"113","author":"Chua","year":"2006","journal-title":"Ophthalmology"},{"issue":"1","key":"10.1016\/j.survophthal.2026.04.002_bib13","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-021-96698-6","article-title":"Stepwise low concentration atropine for myopic control: a 10-year cohort study","volume":"11","author":"Chuang","year":"2021","journal-title":"Sci Rep"},{"issue":"9","key":"10.1016\/j.survophthal.2026.04.002_bib14","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1089\/jop.2015.0043","article-title":"Atropine 0.01% eyedrops significantly reduce the progression of childhood myopia","volume":"31","author":"Clark","year":"2015","journal-title":"J Ocul Pharm Ther"},{"key":"10.1016\/j.survophthal.2026.04.002_bib15","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1186\/s12874-016-0189-0","article-title":"Dose-response meta-analysis of differences in means","volume":"16","author":"Crippa","year":"2016","journal-title":"BMC Med Res Method"},{"issue":"5","key":"10.1016\/j.survophthal.2026.04.002_bib16","doi-asserted-by":"crossref","first-page":"1579","DOI":"10.1177\/0962280218773122","article-title":"One-stage dose-response meta-analysis for aggregated data","volume":"28","author":"Crippa","year":"2019","journal-title":"Stat Methods Med Res"},{"issue":"1","key":"10.1016\/j.survophthal.2026.04.002_bib17","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-021-01708-2","article-title":"Safety and efficacy of 0.02% and 0.01% atropine on controlling myopia progression: a 2-year clinical trial","volume":"11","author":"Cui","year":"2021","journal-title":"Sci Rep"},{"issue":"4","key":"10.1016\/j.survophthal.2026.04.002_bib18","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1016\/j.oftal.2017.12.015","article-title":"Superdiluted atropine at 0.01% reduces progression in children and adolescents. A 5 year study of safety and effectiveness","volume":"93","author":"Diaz-Llopis","year":"2018","journal-title":"Arch De la Soc Espa\u00f1ola De Oftalmol\u00eda (Engl Ed)"},{"issue":"7543","key":"10.1016\/j.survophthal.2026.04.002_bib19","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1038\/519276a","article-title":"The myopia boom","volume":"519","author":"Dolgin","year":"2015","journal-title":"Nature"},{"issue":"9","key":"10.1016\/j.survophthal.2026.04.002_bib20","doi-asserted-by":"crossref","first-page":"925","DOI":"10.1002\/sim.4780140911","article-title":"Estimating the minimum therapeutically effective dose of a compound via regression modelling and percentile estimation","volume":"14","author":"Filloon","year":"1995","journal-title":"Stat Med"},{"issue":"6","key":"10.1016\/j.survophthal.2026.04.002_bib21","doi-asserted-by":"crossref","first-page":"624","DOI":"10.1001\/jamaophthalmol.2017.1091","article-title":"Efficacy and adverse effects of atropine in childhood myopia: a meta-analysis","volume":"135","author":"Gong","year":"2017","journal-title":"JAMA Ophthalmol"},{"issue":"7650","key":"10.1016\/j.survophthal.2026.04.002_bib22","doi-asserted-by":"crossref","first-page":"924","DOI":"10.1136\/bmj.39489.470347.AD","article-title":"GRADE: an emerging consensus on rating quality of evidence and strength of recommendations","volume":"336","author":"Guyatt","year":"2008","journal-title":"Bmj"},{"issue":"3","key":"10.1016\/j.survophthal.2026.04.002_bib23","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1016\/j.ophtha.2021.10.016","article-title":"Efficacy and safety of 8 atropine concentrations for myopia control in children: a network meta-analysis","volume":"129","author":"Ha","year":"2022","journal-title":"Ophthalmology"},{"issue":"4","key":"10.1016\/j.survophthal.2026.04.002_bib24","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1167\/iovs.61.4.49","article-title":"The complications of myopia: a review and meta-analysis","volume":"61","author":"Haarman","year":"2020","journal-title":"Invest Ophthalmol Vis Sci"},{"issue":"24","key":"10.1016\/j.survophthal.2026.04.002_bib25","first-page":"1859","article-title":"Combination with different anticholinergic eyedrops for the treatment of children myopia","volume":"99","author":"Han","year":"2019","journal-title":"Zhonghua yi xue za zhi"},{"issue":"1","key":"10.1016\/j.survophthal.2026.04.002_bib26","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1186\/s12886-023-03177-9","article-title":"Safety and efficacy of 0.01% and 0.1% low-dose atropine eye drop regimens for reduction of myopia progression in Danish children: a randomized clinical trial examining one-year effect and safety","volume":"23","author":"Hansen","year":"2023","journal-title":"BMC Ophthalmol"},{"key":"10.1016\/j.survophthal.2026.04.002_bib27","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1007\/s10384-021-00822-y","article-title":"Efficacy and safety of 0.01% atropine for prevention of childhood myopia in a 2-year randomized placebo-controlled study","volume":"65","author":"Hieda","year":"2021","journal-title":"Jpn J Ophthalmol"},{"key":"10.1016\/j.survophthal.2026.04.002_bib28","unstructured":"Higgins J.P.T., Thomas J., Chandler J., Cumpston M., Li T., Page M.J., Welch V.A. Cochrane Handbook for Systematic Reviews of Interventions version 6.4. Cochrane; 2023."},{"issue":"5","key":"10.1016\/j.survophthal.2026.04.002_bib29","doi-asserted-by":"crossref","first-page":"1036","DOI":"10.1016\/j.ophtha.2016.01.006","article-title":"Global prevalence of myopia and high myopia and temporal trends from 2000 through 2050","volume":"123","author":"Holden","year":"2016","journal-title":"Ophthalmology"},{"key":"10.1016\/j.survophthal.2026.04.002_bib30","unstructured":"Hu L., Lin J., Li J., Ji C.Y., L X. Efficacy of 0.01% atropine inmyopie children of different ages. Guoji Yanke Zazhi( Int Eye Sci);23(3):477-482."},{"issue":"4","key":"10.1016\/j.survophthal.2026.04.002_bib31","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1016\/j.ophtha.2015.11.010","article-title":"Efficacy comparison of 16 interventions for myopia control in children: a network meta-analysis","volume":"123","author":"Huang","year":"2016","journal-title":"Ophthalmology"},{"issue":"2","key":"10.1016\/j.survophthal.2026.04.002_bib32","doi-asserted-by":"crossref","first-page":"325","DOI":"10.3390\/jpm13020325","article-title":"Myopia control with low-dose atropine in European children: six-month results from a randomized, double-masked, placebo-controlled, Multicenter study","volume":"13","author":"Hvid-Hansen","year":"2023","journal-title":"J Pers Med"},{"issue":"2","key":"10.1016\/j.survophthal.2026.04.002_bib33","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1080\/09286580802624442","article-title":"Age of first distance prescription and final myopic refractive error","volume":"16","author":"Iribarren","year":"2009","journal-title":"Ophthalmic Epidemiol"},{"issue":"3","key":"10.1016\/j.survophthal.2026.04.002_bib34","doi-asserted-by":"crossref","first-page":"434","DOI":"10.1038\/s41433-023-02718-2","article-title":"Low concentration atropine and myopia: a narrative review of the evidence for United Kingdom based practitioners","volume":"38","author":"Jawaid","year":"2024","journal-title":"Eye"},{"issue":"2","key":"10.1016\/j.survophthal.2026.04.002_bib35","first-page":"171","article-title":"A point of minimal important difference (MID): a critique of terminology and methods","volume":"11","author":"King","year":"2011","journal-title":"Expert Rev Pharm Outcomes Res"},{"key":"10.1016\/j.survophthal.2026.04.002_bib36","first-page":"1","article-title":"Calculation of the minimum clinically important difference (MCID) using different methodologies: case study and practical guide","author":"Klukowska","year":"2024","journal-title":"Eur Spine J"},{"key":"10.1016\/j.survophthal.2026.04.002_bib37","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1007\/s40123-019-00217-w","article-title":"Atropine 0.01% eye drops for myopia control in American children: a multiethnic sample across three US sites","volume":"8","author":"Larkin","year":"2019","journal-title":"Ophthalmol Ther"},{"issue":"9","key":"10.1016\/j.survophthal.2026.04.002_bib38","doi-asserted-by":"crossref","first-page":"1001","DOI":"10.1111\/ceo.14148","article-title":"Low-concentration atropine eyedrops for myopia control in a multi-racial cohort of Australian children: a randomised clinical trial","volume":"50","author":"Lee","year":"2022","journal-title":"Clin & Exp Ophthalmol"},{"issue":"2","key":"10.1016\/j.survophthal.2026.04.002_bib39","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1111\/j.2041-210X.2010.00063.x","article-title":"A unified approach to model selection using the likelihood ratio test","volume":"2","author":"Lewis","year":"2011","journal-title":"Methods Ecol Evol"},{"issue":"1","key":"10.1016\/j.survophthal.2026.04.002_bib40","first-page":"484","article-title":"Effect of Atropine 0.01% Eye Drops on the Difference in Refraction and Axial Length between Right and Left Eyes","volume":"66","author":"Liang","year":"2023","journal-title":"Ophthalmic Res"},{"issue":"3","key":"10.1016\/j.survophthal.2026.04.002_bib41","doi-asserted-by":"crossref","first-page":"e245","DOI":"10.1111\/aos.15761","article-title":"Myopia outcome study of atropine in children: two-year result of daily 0.01% atropine in a European population","volume":"102","author":"Loughman","year":"2024","journal-title":"Acta Ophthalmol"},{"issue":"10","key":"10.1016\/j.survophthal.2026.04.002_bib42","first-page":"1657","article-title":"The diluted atropine for inhibition of myopia progression in Korean children","volume":"11","author":"Moon","year":"2018","journal-title":"Int J Ophthalmol"},{"issue":"9827","key":"10.1016\/j.survophthal.2026.04.002_bib43","doi-asserted-by":"crossref","first-page":"1739","DOI":"10.1016\/S0140-6736(12)60272-4","article-title":"Myopia","volume":"379","author":"Morgan","year":"2012","journal-title":"Lancet"},{"issue":"10","key":"10.1016\/j.survophthal.2026.04.002_bib44","doi-asserted-by":"crossref","first-page":"1499","DOI":"10.1016\/j.jfo.2021.07.005","article-title":"Myopia progression and axial elongation in Spanish children: efficacy of atropine 0.01% eye-drops","volume":"44","author":"Moriche-Carretero","year":"2021","journal-title":"J Fr D\u2032Ophtalmol"},{"issue":"5","key":"10.1016\/j.survophthal.2026.04.002_bib45","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1136\/bjo-2022-322808","article-title":"Five-year results of atropine 0.01% efficacy in the myopia control in a European population","volume":"108","author":"Moriche-Carretero","year":"2024","journal-title":"Br J Ophthalmol"},{"issue":"7","key":"10.1016\/j.survophthal.2026.04.002_bib46","doi-asserted-by":"crossref","first-page":"1444","DOI":"10.3390\/jcm10071444","article-title":"The effect of long-term low-dose atropine on refractive progression in myopic Australian school children","volume":"10","author":"Myles","year":"2021","journal-title":"J Clin Med"},{"key":"10.1016\/j.survophthal.2026.04.002_bib47","doi-asserted-by":"crossref","first-page":"n71","DOI":"10.1136\/bmj.n71","article-title":"The PRISMA 2020 statement: an updated guideline for reporting systematic reviews","volume":"372","author":"Page","year":"2021","journal-title":"BMJ"},{"issue":"8","key":"10.1016\/j.survophthal.2026.04.002_bib48","doi-asserted-by":"crossref","first-page":"756","DOI":"10.1001\/jamaophthalmol.2023.2855","article-title":"Low-dose 0.01% atropine eye drops vs placebo for myopia control: a randomized clinical trial","volume":"141","author":"Repka","year":"2023","journal-title":"JAMA Ophthalmol"},{"issue":"8","key":"10.1016\/j.survophthal.2026.04.002_bib49","doi-asserted-by":"crossref","first-page":"e1136","DOI":"10.1111\/aos.14166","article-title":"Efficacy of atropine 0.01% for the treatment of childhood myopia in European patients","volume":"97","author":"Sacchi","year":"2019","journal-title":"Acta Ophthalmol"},{"issue":"9","key":"10.1016\/j.survophthal.2026.04.002_bib50","doi-asserted-by":"crossref","first-page":"1367","DOI":"10.1016\/j.ophtha.2021.01.026","article-title":"Atropine for the treatment of childhood myopia in India: multicentric randomized trial","volume":"128","author":"Saxena","year":"2021","journal-title":"Ophthalmology"},{"key":"10.1016\/j.survophthal.2026.04.002_bib51","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1016\/j.jclinepi.2022.07.015","article-title":"GRADE guidance 35: update on rating imprecision for assessing contextualized certainty of evidence and making decisions","volume":"150","author":"Sch\u00fcnemann","year":"2022","journal-title":"J Clin Epidemiol"},{"issue":"9","key":"10.1016\/j.survophthal.2026.04.002_bib52","doi-asserted-by":"crossref","first-page":"3373","DOI":"10.4103\/ijo.IJO_256_22","article-title":"Effect of atropine 0.01% on progression of myopia","volume":"70","author":"Sen","year":"2022","journal-title":"Indian J Ophthalmol"},{"issue":"4","key":"10.1016\/j.survophthal.2026.04.002_bib53","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1080\/02713683.2022.2162925","article-title":"Low dose atropine in preventing the progression of childhood myopia: a randomised controlled trial","volume":"48","author":"Sharma","year":"2023","journal-title":"Curr Eye Res"},{"issue":"1","key":"10.1016\/j.survophthal.2026.04.002_bib54","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1089\/jop.1999.15.85","article-title":"Effects of different concentrations of atropine on controlling myopia in myopic children","volume":"15","author":"Shih","year":"1999","journal-title":"J Ocul Pharm Ther"},{"issue":"3","key":"10.1016\/j.survophthal.2026.04.002_bib55","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1034\/j.1600-0420.2001.790304.x","article-title":"An intervention trial on efficacy of atropine and multi-focal glasses in controlling myopic progression","volume":"79","author":"Shih","year":"2001","journal-title":"Acta Ophthalmol Scand"},{"key":"10.1016\/j.survophthal.2026.04.002_bib56","article-title":"Dose-response meta-analysis: application and practice using the R software","volume":"41","author":"Shim","year":"2019","journal-title":"Epidemiol Health"},{"issue":"6","key":"10.1016\/j.survophthal.2026.04.002_bib57","doi-asserted-by":"crossref","first-page":"2314","DOI":"10.3390\/jcm12062314","article-title":"The effectiveness and tolerability of atropine eye drops for myopia control in non-asian regions","volume":"12","author":"Simonaviciute","year":"2023","journal-title":"J Clin Med"},{"issue":"4","key":"10.1016\/j.survophthal.2026.04.002_bib58","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1089\/jop.2011.0017","article-title":"Atropine in ameliorating the progression of myopia in children with mild to moderate myopia: a meta-analysis of controlled clinical trials","volume":"27","author":"Song","year":"2011","journal-title":"J Ocul Pharm Ther"},{"key":"10.1016\/j.survophthal.2026.04.002_bib59","doi-asserted-by":"crossref","first-page":"l4898","DOI":"10.1136\/bmj.l4898","article-title":"RoB 2: a revised tool for assessing risk of bias in randomised trials","volume":"366","author":"Sterne","year":"2019","journal-title":"BMJ"},{"issue":"3","key":"10.1016\/j.survophthal.2026.04.002_bib60","doi-asserted-by":"crossref","first-page":"572","DOI":"10.1016\/j.ophtha.2008.10.020","article-title":"Atropine for the treatment of childhood myopia: effect on myopia progression after cessation of atropine","volume":"116","author":"Tong","year":"2009","journal-title":"Ophthalmology"},{"issue":"27","key":"10.1016\/j.survophthal.2026.04.002_bib61","doi-asserted-by":"crossref","DOI":"10.1097\/MD.0000000000007371","article-title":"Atropine 0.5% eyedrops for the treatment of children with low myopia: A randomized controlled trial","volume":"96","author":"Wang","year":"2017","journal-title":"Med (Baltim)"},{"issue":"8","key":"10.1016\/j.survophthal.2026.04.002_bib62","doi-asserted-by":"crossref","first-page":"722","DOI":"10.1001\/jamaophthalmol.2024.2295","article-title":"0.01% atropine eye drops in children with myopia and intermittent exotropia: The AMIXT Randomized Clinical Trial","volume":"142","author":"Wang","year":"2024","journal-title":"JAMA Ophthalmol"},{"issue":"11","key":"10.1016\/j.survophthal.2026.04.002_bib63","doi-asserted-by":"crossref","first-page":"1178","DOI":"10.1001\/jamaophthalmol.2020.3820","article-title":"Safety and efficacy of low-dose atropine eyedrops for the treatment of myopia progression in Chinese children: a randomized clinical trial","volume":"138","author":"Wei","year":"2020","journal-title":"JAMA Ophthalmol"},{"issue":"3","key":"10.1016\/j.survophthal.2026.04.002_bib64","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1111\/opo.12042","article-title":"Age of myopia onset in a B ritish population-based twin cohort","volume":"33","author":"Williams","year":"2013","journal-title":"Ophthalmic Physiol Opt"},{"issue":"5","key":"10.1016\/j.survophthal.2026.04.002_bib65","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1089\/jop.2011.0027","article-title":"The long-term results of using low-concentration atropine eye drops for controlling myopia progression in schoolchildren","volume":"27","author":"Wu","year":"2011","journal-title":"J Ocul Pharm Ther"},{"issue":"3","key":"10.1016\/j.survophthal.2026.04.002_bib66","doi-asserted-by":"crossref","first-page":"656","DOI":"10.47391\/JPMA.6241","article-title":"Effect of 0.01% Atropine on diopter and optic axis in adolescents and children with myopia","volume":"73","author":"Xia","year":"2023","journal-title":"JPMA J Pak Med Assoc"},{"issue":"12","key":"10.1016\/j.survophthal.2026.04.002_bib67","doi-asserted-by":"crossref","first-page":"1812","DOI":"10.1136\/bjo-2022-321272","article-title":"Effect of atropine, orthokeratology and combined treatments for myopia control: a 2-year stratified randomised clinical trial","volume":"107","author":"Xu","year":"2023","journal-title":"Br J Ophthalmol"},{"issue":"1","key":"10.1016\/j.survophthal.2026.04.002_bib68","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1016\/j.ophtha.2018.05.029","article-title":"Low-concentration atropine for myopia progression (LAMP) study: a randomized, double-blinded, placebo-controlled trial of 0.05%, 0.025%, and 0.01% atropine eye drops in myopia control","volume":"126","author":"Yam","year":"2019","journal-title":"Ophthalmology"},{"issue":"7","key":"10.1016\/j.survophthal.2026.04.002_bib69","doi-asserted-by":"crossref","first-page":"910","DOI":"10.1016\/j.ophtha.2019.12.011","article-title":"Two-year clinical trial of the low-concentration atropine for myopia progression (LAMP) study: phase 2 report","volume":"127","author":"Yam","year":"2020","journal-title":"Ophthalmology"},{"issue":"3","key":"10.1016\/j.survophthal.2026.04.002_bib70","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1016\/j.ophtha.2021.10.002","article-title":"Three-year clinical trial of low-concentration atropine for myopia progression (LAMP) study: continued versus washout: phase 3 report","volume":"129","author":"Yam","year":"2022","journal-title":"Ophthalmology"},{"issue":"5","key":"10.1016\/j.survophthal.2026.04.002_bib71","first-page":"180","article-title":"Comparison of the effect of atropine and cyclopentolate on myopia","volume":"21","author":"Yen","year":"1989","journal-title":"Ann Ophthalmol"},{"issue":"5","key":"10.1016\/j.survophthal.2026.04.002_bib72","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1016\/j.jaapos.2015.04.006","article-title":"Therapeutic effect of atropine 1% in children with low myopia","volume":"19","author":"Yi","year":"2015","journal-title":"J AAPOS"},{"issue":"10","key":"10.1016\/j.survophthal.2026.04.002_bib73","doi-asserted-by":"crossref","first-page":"990","DOI":"10.1001\/jamaophthalmol.2023.2097","article-title":"Efficacy and safety of 0.01% and 0.02% atropine for the treatment of pediatric myopia progression over 3 years: a randomized clinical trial","volume":"141","author":"Zadnik","year":"2023","journal-title":"JAMA Ophthalmol"},{"key":"10.1016\/j.survophthal.2026.04.002_bib74","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1016\/j.jclinepi.2022.07.014","article-title":"GRADE Guidance 34: update on rating imprecision using a minimally contextualized approach","volume":"150","author":"Zeng","year":"2022","journal-title":"J Clin Epidemiol"},{"issue":"3","key":"10.1016\/j.survophthal.2026.04.002_bib75","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1080\/09286586.2023.2232462","article-title":"Effect of low-concentration atropine eye drops in controlling the progression of myopia in children: a one-and two-year follow-up study","volume":"31","author":"Zhang","year":"2024","journal-title":"Ophthalmic Epidemiol"},{"issue":"3","key":"10.1016\/j.survophthal.2026.04.002_bib76","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2023.4080","article-title":"Prevalence of Myopia in Children Before, During, and After COVID-19 Restrictions in Hong Kong","volume":"6","author":"Zhang","year":"2023","journal-title":"JAMA Netw Open"},{"key":"10.1016\/j.survophthal.2026.04.002_bib77","article-title":"Advances in myopia control strategies for children","author":"Zhang","year":"2024","journal-title":"Br J Ophthalmol"},{"key":"10.1016\/j.survophthal.2026.04.002_bib78","doi-asserted-by":"crossref","DOI":"10.1016\/j.ophtha.2024.03.013","article-title":"Five-year clinical trial of the low-concentration atropine for myopia progression (LAMP) study: phase 4 report","author":"Zhang","year":"2024","journal-title":"Ophthalmology"},{"issue":"9","key":"10.1016\/j.survophthal.2026.04.002_bib79","doi-asserted-by":"crossref","first-page":"1011","DOI":"10.1016\/j.ophtha.2024.03.013","article-title":"Five-year clinical trial of the low-concentration atropine for myopia progression (LAMP) study: phase 4 report","volume":"131","author":"Zhang","year":"2024","journal-title":"Ophthalmology"},{"key":"10.1016\/j.survophthal.2026.04.002_bib80","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12886-020-01746-w","article-title":"Efficacy and safety of atropine to control myopia progression: a systematic review and meta-analysis","volume":"20","author":"Zhao","year":"2020","journal-title":"BMC Ophthalmol"},{"key":"10.1016\/j.survophthal.2026.04.002_bib81","doi-asserted-by":"crossref","first-page":"1011","DOI":"10.1007\/s10792-020-01658-0","article-title":"Clinical efficacy of 0.01% atropine in retarding the progression of myopia in children","volume":"41","author":"Zhao","year":"2021","journal-title":"Int Ophthalmol"},{"issue":"6","key":"10.1016\/j.survophthal.2026.04.002_bib82","doi-asserted-by":"crossref","first-page":"939","DOI":"10.18240\/ijo.2023.06.17","article-title":"X-F. 0.05% atropine on control of myopia progression in Chinese school children: a randomized 3-year clinical trial","volume":"16","author":"Zhu","year":"2023","journal-title":"Int J Ophthalmol"},{"key":"10.1016\/j.survophthal.2026.04.002_bib83","doi-asserted-by":"crossref","first-page":"100122","DOI":"10.1016\/j.apjo.2024.100122","article-title":"Low-concentration atropine for controlling myopia onset and progression in East Asia","volume":"13","author":"Zaabaar","year":"2024","journal-title":"Asia Pac J Ophthalmol (Phila)"},{"key":"10.1016\/j.survophthal.2026.04.002_bib84","doi-asserted-by":"crossref","first-page":"100161","DOI":"10.1016\/j.apjo.2025.100161","article-title":"The whole life cycle myopia management","volume":"14","author":"Chen","year":"2025","journal-title":"Asia Pac J Ophthalmol (Phila)"},{"key":"10.1016\/j.survophthal.2026.04.002_bib85","doi-asserted-by":"crossref","first-page":"100138","DOI":"10.1016\/j.apjo.2025.100138","article-title":"Role of caffeine in slowing progression of myopia: 1-year results from a prospective, longitudinal clinical trial","volume":"14","author":"Tran","year":"2025","journal-title":"Asia Pac J Ophthalmol (Phila)"}],"container-title":["Survey of Ophthalmology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0039625726000524?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0039625726000524?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,9,10]],"date-time":"2026-09-10T20:06:11Z","timestamp":1789070771000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0039625726000524"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,11]]},"references-count":85,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2026,11]]}},"alternative-id":["S0039625726000524"],"URL":"https:\/\/doi.org\/10.1016\/j.survophthal.2026.04.002","relation":{},"ISSN":["0039-6257"],"issn-type":[{"value":"0039-6257","type":"print"}],"subject":[],"published":{"date-parts":[[2026,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Efficacy, tolerability, and threshold effect of atropine eye drops for myopia control: A systematic review and dose-response meta-analysis","name":"articletitle","label":"Article Title"},{"value":"Survey of Ophthalmology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.survophthal.2026.04.002","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}